LXRX Share Price Performance
US$1.60
1.10 (219.30%)
52.4% undervalued intrinsic discount
US$3.36
Fair Value
Price US$1.60
AnalystConsensusTarget US$3.36
AnalystLowTarget US$1.00
AnalystHighTarget US$6.00
Fair ValueUS$3.36
Share Pricen/a
Lexicon Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 30 Fair Values set on narratives written by author
LXRX Community Narratives
AN
Fair Value US$3.36 52.4% undervalued intrinsic discount
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
0users have liked this narrative
1users have commented on this narrative
24users have followed this narrative
AN
Fair Value US$1 60.0% overvalued intrinsic discount
Regulatory Headwinds And Partnership Risks Will Pressure Cardiometabolic Pipeline Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$6 73.3% undervalued intrinsic discount
Cardiometabolic And Neuropathic Tailwinds Will Drive Major Upside Over The Long Term
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Key Takeaways Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets. Strategic licensing and cost reduction initiatives aim to boost revenue streams while improving net margins and profitability.Read more
435
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
24users have followed this narrative
AN
US$3.36
52.4% undervalued intrinsic discount
Fair Value
Profit Margin
19.89%
Future PE
156.08x
Price in 2029
US$4.11
Regulatory Headwinds And Partnership Risks Will Pressure Cardiometabolic Pipeline Prospects
Catalysts About Lexicon Pharmaceuticals Lexicon Pharmaceuticals focuses on developing and commercializing cardiometabolic and neuroscience therapies, including INPEFA and a pipeline of late stage drug candidates such as pilavapadin and sotagliflozin. What are the underlying business or industry changes driving this perspective?Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$1
60.0% overvalued intrinsic discount
Fair Value
Profit Margin
20.87%
Future PE
277.42x
Price in 2029
US$1.22
Cardiometabolic And Neuropathic Tailwinds Will Drive Major Upside Over The Long Term
Catalysts About Lexicon Pharmaceuticals Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing and partnering innovative medicines for cardiometabolic diseases and neuropathic pain. What are the underlying business or industry changes driving this perspective?Read more
39
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$6
73.3% undervalued intrinsic discount
Fair Value
Profit Margin
20.88%
Future PE
218.16x
Price in 2028
US$7.34
Trending Discussion
Recently Updated Narratives
AN
LXRX: Phase 3 Pain Program Progress And Partnership Expectations May Support Upside
Fair Value: US$3.36 52.4% undervalued intrinsic discount
24 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Headwinds And Partnership Risks Will Pressure Cardiometabolic Pipeline Prospects
Fair Value: US$1 60.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Cardiometabolic And Neuropathic Tailwinds Will Drive Major Upside Over The Long Term
Fair Value: US$6 73.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lexicon Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.12
- 86.82%
- -101.08%
- 50.2%
About LXRX
- Founded
- 1995
- Employees
- 81
- CEO
- WebsiteView website
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
